Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL2930007 | 0.89 | SIGMAR1 (0.57) | CYP2A13SIGMAR1SMN1; SMN2KDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL2931430 | 0.89 | SIGMAR1 (0.58) | CYP2A13SIGMAR1HTTRECQLPDE4B | |
| SCHEMBL4115394 | 0.81 | SIGMAR1 (0.72) | CYP2A13SIGMAR1HTTRECQLPDE4B | |
| SCHEMBL4109682 | 0.81 | CYP2A13 (1.00) | CYP2A13SIGMAR1HTTSMN1; SMN2KDM4E | |
| SCHEMBL2923321 | 0.80 | CYP2A13 (0.61) | CYP2A13SIGMAR1HTTRECQLPDE4B | |
| SCHEMBL9610926 | 0.77 | CYP2A13 (0.69) | CYP2A13SIGMAR1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2250508 | 0.77 | CYP2A13 (0.69) | CYP2A13SIGMAR1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2924117 | 0.77 | CYP2A13 (0.60) | CYP2A13SIGMAR1HTTRECQLSMN1; SMN2 | |
| SCHEMBL2923318 | 0.76 | CYP2A13 (0.63) | CYP2A13SIGMAR1HTTRECQLPDE4B | |
| SCHEMBL3304078 | 0.76 | CYP2A13 (0.63) | CYP2A13SIGMAR1HTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | CYP2A13 2952/4885SIGMAR1 2671/4885HTT 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.